tbuckley/cabot-search huggingface dataset:
AB0922 Clinical Characteristics of Crystal Deposition Diseases of Cervical Spine: A Comparison Between Crowned Dens Syndrome and Retropharyngeal Calcific Tendinitis
Authors: K. Fujikawa, A. Mizokami, Y. Nishiura, K. Nagasato, A. Kawakami
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Crowned dens syndrome (CDS) and Retropharyngeal calcific tendinitis (RCT) are both crystal deposition diseases affected in cervical spine causing acute neck pain. Differential diagnosis of the above two diseases is sometimes difficult since both induce neck symptoms. <h3>Objectives</h3> To examine the characteristics of CDS and RCT found in daily clinical practice. <h3>Methods</h3> Sixteen patients with CDS and five patients with RCT were consecutively enrolled who undergoing medical treatment at the department of Rheumatology and Neurology, Isahaya General Hospital from January 2010 to December 2013. We have evaluated the clinical features, labolatory data and radiographic findings of cervical spine. <h3>Results</h3> All of the 21 patients had acute neck pain and almost all had limited range of neck motion. Higher age, fever, peripheral arthritis, shoulder pain and higher CRP were predominantly found in CDS whereas swallowing pain was specific in RCT. The proportion of calcification was clearly different in both diseases since that was found around the odontoid process in CDS whereas prevertebral space in RCT determined by cervical computed tomography (CT). All of the 21 patients had acute neck pain and almost all had limited range of neck motion. Higher age, fever, peripheral arthritis, shoulder pain and higher CRP were predominantly found in CDS whereas swallowing pain was specific in RCT. The proportion of calcification was clearly different in both diseases since that was found around the odontoid process in CDS whereas prevertebral space in RCT determined by cervical computed tomography (CT). <h3>Conclusions</h3> CDS and RCT can be differentially diagnosed by considering characteristic clinical manifestations and cervical CT findings. <h3>Disclosure of Interest</h3> None declared
SAT0135 What Factors are Associated with Methotrexate Monotherapy in Recent Onset Rheumatoid Arthritis? Results from a UK Nationwide Observational Study (RAMS): Table 1.
Authors: J. Humphreys, J. Sergeant, J. Anderson, A. Barton, K. Hyrich, S. Verstappen
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> In the UK, methotrexate (MTX) monotherapy is only recommended in the initial management of patients presenting with RA where there are contraindications to combination therapy, or multiple comorbidities. However it is not clear how frequently and why different treatment strategies are used in routine practice. <h3>Objectives</h3> To identify, in a national cohort, the frequency of methotrexate monotherapy and examine factors associated with its prescription. <h3>Methods</h3> The Rheumatoid Arthritis Medications Study (RAMS) recruited patients with RA starting MTX for the first time since 2008 across the UK, with symptom duration &lt;2 years. Data, including demographics, comorbidity, medication history, smoking history, CRP, RF, DAS28 and HAQ were recorded at start of therapy. Subsequent medication changes were detailed at 3 and 6 month follow-up. Patients were classified as being on MTX monotherapy if they were not either: (1) currently taking or started on another DMARD within 90 days of methotrexate start date, or (2) currently taking or started on oral steroids (for at least 30 days) within 30 days of methotrexate start date. Univariate and multivariate logistic regression analyses were applied to assess the association between MTX monotherapy and baseline age, gender, disease duration, CRP, RF, HAQ, DAS28, smoking status, comorbidity and year of registration. <h3>Results</h3> Of 731 patients included 493 (67%) were prescribed MTX monotherapy (table 1). 193 (80%) patients on combination therapy were treated with another DMARD and 48 (20%) with steroids. Older age was associated with increased odds of monotherapy and RF positivity with combination therapy (table 1). <h3>Conclusions</h3> Despite current UK recommendations, in our study MTX was more commonly prescribed as monotherapy than in combination with other DMARDs. Older patients were more frequently treated with monotherapy; however no association was seen with the presence of multiple comorbidities. Others factors such as patient preference may be contributing to these prescribing practices. <h3>Disclosure of Interest</h3> None declared
A critical discussion of DSM-III dysthymic disorder
Authors: J H Kocsis, A J Frances
Journal: American Journal of Psychiatry (1987)

The authors review the history of the concept of dysthymia and the literature on the epidemiology, course, and treatment of chronic depression. They present a critical discussion of DSM-III and DSM-III-R criteria for dysthymic disorder. On the basis of this review, they suggest that future revisions of the nomenclature include further subcategorization of chronic depressive disorders and that the term "dysthymic disorder" be reserved for chronic depressive disorders with an insidious onset at an early age. The relationships between dysthymic disorders and personality disorders and the response of subcategories of chronic depression to different treatment modalities need to be researched.
Cerebral laterality and psychiatry: a review of the literature
Authors: B E Wexler
Journal: American Journal of Psychiatry (1980)

The two sides of the human brain are functionally and anatomically different. Research methods based on this cerebral laterality have been used to investigate regional brain function in psychiatric illness. The author describes the functional and anatomic differences between the two sides of the brain, the research methods based on these differences, and the results of studies that have used these methods to investigate brain dysfunction in psychiatric illness.
Child Health
Authors: Jody W. Zylke
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Scintigraphic Identification of Gastric Tissue in a Mediastinal Mass
Authors: Ismini C. Mainta, Xavier Montet, Jean-Pierre Willi, Pavel Dulguerov, Olivier Rager
Journal: Clinical Nuclear Medicine (2015)

We present a 99mTc pertechnetate scintigraphy performed in a 64-year-old woman to investigate a mediastinal cystic mass in search of residual gastric mucosa after gastrectomy. She had a history of esophagectomy and gastric pull-up for esophageal cancer. Postoperative leakage necessitated ablation of the gastric pull-up and reconstruction using part of the colon. Oral realimentation resulted in mediastinal pain and brownish discharge within the trachea, raising the suspicion of residual gastric pouch. SPECT/CT demonstrated increased tracer uptake in the median part of the mediastinal cyst, and a biopsy confirmed the presence gastric mucosa.
Integration of oncology and palliative care (PC): A systematic review.
Authors: David Hui, Yu Jung Kim, Yi Zhang, Jichan Park, Florian Strasser, Nathan Cherny, Stein Kaasa, Mellar P. Davis, Eduardo Bruera
Journal: Journal of Clinical Oncology (2014)

13 Background: Both ASCO and ESMO strongly endorse integrating oncology and PC; however, a global consensus on indicators of integration is currently lacking. To better understand what “integration” entails, we conducted a systematic review to identify articles addressing the clinical, education, and administrative indicators of integration. Methods: We searched Ovid MEDLINE and Ovid EMBase between 1948 to 2013 using the search terms “neoplasms”, “integration”, and “Palliative Care” or “Supportive Care”. Two researchers independently reviewed each citation for inclusion, and then extracted the indicators related to integration. The inter-rater agreement was high (kappa=0.96, P&lt;0.001). Results: Our initial search identified 411 publications, and 97 were included in the final sample. 58 (60%) were review articles and 31 (32%) were original articles. The number of articles on integration increased significantly between 1991 and 2013 (P&lt;0.001), with 63 (65%) articles published in 2010 or later. Among these articles, 30 (31%), 16 (16%), 15 (15%) and 8 (8%) articles, respectively, discussed the role of outpatient clinics, community care, PC units, and inpatient consultation teams in integration. 53 (55%) articles addressed various processes for integration, including routine symptom screening (N=16), interdisciplinary teams (N=16), guidelines (N=11), referral criteria (N=10), embedded clinics (N=5) and clinical care pathways (N=5). 31 (32%) mentioned “early” involvement of PC, 11 (11%) provided a specific timing, and 24 (25%) discussed referral criteria. 33 (34%) articles addressed educational strategies for integration, such as training programs (N=13), PC rotations (N=3), and continuing medical education (N=4). 14 (14%) articles described research indicators and 21 (22%) on administrative indicators. No articles specifically defined the term “integration” nor discussed standardized outcomes of integration. Conclusions: Integration was a heterogeneously defined concept. Our systematic review highlighted 40 clinical, educational, research and administrative indicators on integration. This study is part of an international effort to further develop refined and widely endorsed criteria for broad application.
PTH-248 The development of small intestinal bacterial overgrowth and lactose intolerance during modern pelvic chemoradiotherapy: Abstract PTH-248 Table 1
Authors: KL White, CC Henson, J Glennon, S Burden, S Lal, SE Davidson, J McLaughlin
Journal: Gut (2015)

<h3>Introduction</h3> Diarrhoea is common during pelvic chemoradiotherapy and is multifactorial in origin. Previous studies show a rate of 26% small intestinal bacterial overgrowth (SIBO) and 15–44% lactose intolerance during the acute toxicity phase. However radiotherapy treatment has developed to provide more targeted treatment to the tumour, and spare organs at risk such as the small bowel. We aimed to determine the rate of SIBO and lactose intolerance in patients receiving newer techniques at our centre. <h3>Method</h3> This study was part of a trial evaluating the use of a gastrointestinal intervention for patients with cervical and bladder cancer receiving pelvic chemoradiotherapy. When patients developed lower gastrointestinal symptoms, hydrogen-methane breath tests were performed using the Quintron Breathtracker to detect SIBO and lactose intolerance. Demographic and treatment data were recorded in the trial documentation. <h3>Results</h3> Twenty patients had hydrogen methane breath testing for SIBO and 17 for lactose intolerance. Nine of these patients had cervical cancer and 11 had bladder cancer. Of the patients with bladder cancer, 10 were male. All patients received 20 fractions of radiotherapy over 4 weeks. See Table 1for full demographics. Glucose hydrogen methane breath testing was performed a median of 19 days after the start of radiotherapy and lactose hydrogen methane breath testing a median of 27 days after. SIBO was diagnosed in 21% (4/19) (1 test was inconclusive) by a rise in hydrogen in all cases. Of patients with cervical cancer 38% (3/8) had SIBO compared with 9% (1/11) patients with bladder cancer. Lactose intolerance was diagnosed in 29% (5/17) patients by a rise in hydrogen in all cases. Of the bladder group 30% (3/10) had lactose intolerance while 29% (2/7) of the cervix group tested positive. <h3>Conclusion</h3> The prevalence of SIBO and lactose intolerance in this study is similar to that previously described despite recent advances in radiotherapy treatment suggesting that new techniques do not reduce the risk of small bowel bystander effects. <h3>Disclosure of interest</h3> K. White Grant/ Research Support from: This poster presents independent research funded by the National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant Reference Number PB-PG-0211–10024. The views expressed are those of the author (s) and not necessarily those of the NHS, the NIHR or the Department of Health., C. Henson: None Declared, J. Glennon: None Declared, S. Burden: None Declared, S. Lal: None Declared, S. Davidson: None Declared, J. McLaughlin: None Declared.
THU0019 Association of HLA-B*41:02 with Henoch-Schönlein Purpura in Spanish Individuals Irrespective of the HLA-DRB1 Status
Authors: R. Lόpez-Mejías, F. Genre, B. Sevilla Pérez, S. Castañeda, N. Ortego-Centeno, J. Llorca, B. Ubilla, S. Remuzgo-Martínez, V. Mijares, T. Pina, V. Calvo-Río, A. Márquez, J.A. Miranda-Filloy, A. Navas Parejo, M. Conde-Jaldόn, L. Ortiz-Fernández, D. Argila, M. Aragües, E. Rubio, M. Leόn Luque, J.M. Blanco-Madrigal, E. Galíndez-Aguirregoikoa, F. González Escribano, J.G. Ocejo-Vinyals, J. Martín, R. Blanco, M.Ά. González-Gay
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> To determine whether the <i>human leukocyte antigen</i> (<i>HLA</i>) <i>B</i> alleles are implicated in the susceptibility to Henoch-Schönlein purpura (HSP) in the largest series of Caucasian HSP patients ever assessed for genetic studies. <h3>Methods</h3> The study population was composed of 349 Spanish patients diagnosed with HSP fulfilling the American College of Rheumatology and the Michel <i>et al.</i> classification criteria, and 335 sex and ethnically matched controls. <i>HLA-B</i> phenotypes were determined by sequencing-based typing (SBT) and analyzed by chi-square or Fisher exact test. <h3>Results</h3> A statistically significant increase of <i>HLA-B*41:02</i> allele in HSP patients when compared with controls was found (8.3% versus 1.5% respectively; p=0.0001; OR (odds ratio) =5.76 [2.15-19.3]). These results remained statistically significant after adjusting for Bonferroni correction (p=0.0028). An internal validation also confirmed the susceptibility effect on HSP associated with <i>HLA-B*41:02</i> (OR=5.70 [1.98-16.44]). Since a former study described an association between <i>HLA-DRB1*01:03</i> and HSP susceptibility, we also evaluated the implication of <i>HLA-B*41:02</i> independently of <i>HLA-DRB1*01:03</i>. Interestingly, the association remained statistically significant (p=0.0004, OR=4.97 [1.8-16.9]). No <i>HLA-B</i> association with specific HSP clinical features was found. <h3>Conclusions</h3> Our study indicates that <i>HLA-B*41:02</i> is associated with the susceptibility to HSP in Spanish patients irrespective of <i>HLA-DRB1</i> status. <h3>Acknowledgements</h3> This study was supported by a grant from "Fondo de Investigaciones Sanitarias" PI12/00193 (Spain). RLM is a recipient of a Sara Borrell postdoctoral fellowship from the Instituto de Salud Carlos III at the Spanish Ministry of Health (Spain) (CD12/00425). FG and BU are supported by funds from the RETICS Program (RIER) (RD12/0009/0013). <h3>Disclosure of Interest</h3> None declared
Panic and panic disorder in the United States
Authors: W W Eaton, R C Kessler, H U Wittchen, W J Magee
Journal: American Journal of Psychiatry (1994)

The goal of this study was to determine the prevalence of DSM-III-R panic disorder and to describe its correlates.The study was part of the National Comorbidity Survey, the first psychiatric epidemiologic survey of the entire U.S. population and the first to use DSM-III-R criteria for diagnosis. The 8,098 survey respondents, aged 15-54 years, were given the Composite International Diagnostic Interview. For this report, the data on panic were analyzed, and from them the prevalence of panic disorder and related experiences in the U.S. population was estimated.About 15% of the survey respondents reported the occurrence of a panic attack over their lifetimes, and 3% reported a panic attack in the preceding month. About 1% met the DSM-III-R criteria for panic disorder in the month preceding the interview. Panic attacks and panic disorder had a bimodal age distribution and were associated with female sex and lower educational achievement. Fifty percent of the survey respondents with panic disorder reported no symptoms of agoraphobia. The pattern of prevalence of correlated sociodemographic factors was similar for persons with panic attacks, panic disorder, and panic disorder with agoraphobia.There appears to be no obvious threshold for the diagnosis of panic disorder. Panic disorder and agoraphobia, although highly comorbid, also occur separately.
Observations of a General Practitioner.
Authors: H G WEISS
Journal: Annals of Internal Medicine (1937)

This is an autobiographical book of medical practice written by a practitioner of Fort Covington, New York. It is written in a rough and ready manner with numerous anecdotes. It discusses everything from domestic nursing, diet, pills and prescriptions to all sorts of diseases. There is a clinical index. One is inclined to doubt therapeutic knowledge which says that lobelia, grindelia, euphorbia pilulifera and various herbal preparations are of service in treating asthma. Altogether the book offers a record of practical experience, but it is dispensed with a mass of verbiage.
A developmental view of affective disturbances in the children of affectively ill parents
Authors: L Cytryn, D H McKnew, C Zahn-Waxler, M Radke-Yarrow, T J Gaensbauer, R J Harmon, M Lamour
Journal: American Journal of Psychiatry (1984)

The authors review the various clinical and experimental studies of children of parents with affective illness, spanning infancy, childhood, and early adolescence and including their own and the studies reported in this Special Section of the Journal. They find a clear tendency to early disturbances in these children that seems related to adult affective illness in the areas of affect regulation and social interaction. Although these findings suggest a developmental line of affective illness linking child and adult forms, many issues need further clarification.
Osteonecrosis in Behcet's disease seen on bone scintigraphy.
Authors: Z Yapar, M Kibar, M Soy, S Ozbek
Journal: Clinical Nuclear Medicine (2001)

YAPAR, ZEYNEP M.D.,*; KBAR, MUSTAFA M.D.,*; SOY, MEHMET M.D.† AND; ÖZBEK, SÜLEYMAN M.D.† Author Information
Scintigraphic Detection of Bronchobiliary Fistula in a Patient with Bile in Bronchial Secretions
Authors: CEM KINACI, EROL AKGÜL, DERYA SIRE, GÖKSEL ERSOY, NURETTIN DOLAPCIOGLU, FILIZ BEYCI
Journal: Clinical Nuclear Medicine (2001)

KINACI, CEM M.D.; AKGÜL, EROL M.D.; SIRE, DERYA M.D.; ERSOY , GÖKSEL M.D.; DOLAPCIOGLU, NURETTIN M.D.; BEYCI, FILIZ Author Information
Words
Authors: Susan M Behuniak
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Stress response syndrome occurring after delirium
Authors: T B Mackenzie, M K Popkin
Journal: American Journal of Psychiatry (1980)

Psychiatric treatment of delirium usually focuses on behavioral management during the period of cognitive disturbance. Psychological sequelae have received less attention. The authors suggest that delirium represents a stressful life event that must be assimilated after the cognitive impairment has resolved. Such assimilation may be uniquely impaired because the patient lacks clear and correct information about the event. The authors propose that the psychiatric care of delirium include facilitation of the patient's efforts to obtain and assimilate information about the delirium after its resolution.
Rotten jobs
Authors: Mary Black
Journal: BMJ (2007)

Most patients with non-small cell lung cancer with common epidermal growth factor receptor (EGFR) mutations respond dramatically to EGFR tyrosine kinase inhibitors (TKIs), but data are limited on the response of tumours with uncommon mutations. We present the case of a 68-year-old man with stage IV lung adenocarcinoma with an uncommon EGFR mutation in exon 21 (L861Q). The disease progressed 2 years after he started erlotinib (150 mg daily). Using a transbronchial lung biopsy, we detected additional mutations in exon 20 (T790M) and exon 21 (L858R). He was treated with osimertinib (80 mg daily) and achieved a partial remission. This case demonstrates the value of repeating a biopsy after EGFR-TKI therapy in patients with uncommon EGFR mutations.